Rasio cepet Axsome Therapeutics (AXSM)

Axsome Therapeutics (AXSM) is accelerating drug delivery through the innovative modification of known molecules. The rapid autonomy ratio visualizes the company's ability to cover obligations excluding inventories, where 1.40 reflects the baseline level of the metric. The firm's scientific potential is based on the development of targeted antidepressants, while the commercial success of new products ensures a steady inflow of operating liquidity.

Axsome Therapeutics (AXSM) maintains strong pricing power based on its depression therapy patents, ensuring a steady cash flow. By analyzing the quick ratio, an investor assesses the company's ability to settle short-term liabilities using only cash and accounts receivable—completely excluding inventory—which reveals the business's true financial resilience without relying on illiquid assets.